Kadimastem Overview
Kadimastem develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as amyotrophic lateral sclerosis (ALS) and diabetes. The technology has been developed as a platform enabling the manufacture of islet-like endocrine cells and glia-restricted progenitors. It has potential applications for diabetes and neurodegenerative diseases such as ALS. The therapy is scalable, industrialized, and will be commercialized as a stable off-the-shelf product to reduce the cost of treatments. For its technology, Kadimastem uses pluripotent cells that can multiply infinitely without losing their naive state or ability to become any cell type. The product is produced under GMP guidelines (similar to traditional therapeutics) in order to reach optimal medical results. The company's process differentiates the cells in the lab, before their injection into the patient. The company's process markedly enhances the efficiency of the treatment.
Cumulative Funding Raised Over Time ($)
$6.8MApr 2021
$10.0MNov 2021
$15.2MOct 2018
$20.1MOct 2021
Latest News
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, announced a reverse share split at a 1-for-10 ratio and a merger with Kadimastem Ltd. The reverse split will affect common and preferred shares, and the company will trade under the new symbol NCEL and name NewcelX Ltd. on Nasdaq starting October 31, 2025. The merger and reverse split were approved at a shareholders meeting on September 29, 2025. The merger aims to enhance the companys focus on innovative therapies for central nervous system disorders. VStock Transfer, LLC will manage the exchange process. The merger is expected to bring potential benefits to both NLS and Kadimastem shareholders.
Acquired-byPublic Trading
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for...
NLS Pharmaceutics Ltd., a biopharmaceutical company, has merged with Kadimastem Ltd., a clinical-stage cell therapy company. The merger will form NewCelX Ltd., which will continue the development of the ITOL-102 cell therapy program for Type 1 Diabetes. This program, supported by the BIRD Foundation, aims to develop a stem-cell-derived therapy for diabetes without lifelong immunosuppression. The merger is seen as a strategic move to expand NLSs pipeline into regenerative and metabolic medicine. The collaboration with iTolerance Inc. will continue under the new company, enhancing the development of innovative therapies.
Acquired-byProduct StagePartners
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced...
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced the completion of all material conditions for their merger, which will result in the formation of a new company, NewCelX Ltd. The merger has been approved by Nasdaq, and the new company will be listed on the Nasdaq Capital Market under the ticker symbol NCEL starting October 31, 2025. Kadimastems shares will be delisted from the Tel Aviv Stock Exchange following the merger. The exchange ratio for the merger is set at 0.706 NLS common shares per Kadimastem ordinary share after a reverse share split. The merger is expected to enhance the companies capabilities in developing therapies for central nervous system disorders and neurodegenerative diseases.
Acquired-byPublic Trading
growth-positive
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
Kadimastem, a clinical-stage biotechnology company, has signed a Memorandum of Understanding (MOU) with TargetGene Biotechnologies to collaborate on developing gene-edited cell therapy products. This partnership aims to enhance the therapeutic performance, stability, and safety of cell-based treatments for diseases like ALS and diabetes. The collaboration will continue under the combined company, NewCelX, following the anticipated merger between NLS Pharmaceutics and Kadimastem. The MOU outlines joint R&D activities, technology exchange, and future licensing opportunities, marking a significant step in Kadimastems strategy to expand its pipeline with next-generation therapies. The collaboration is expected to accelerate the creation of scalable, commercially viable treatments, reinforcing Kadimastems commitment to delivering transformative solutions to patients worldwide.
Partners
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on...
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, and Kadimastem Ltd., an advanced clinical-stage cell therapy company, announced a merger. The merger will result in the formation of NewcelX Ltd., with Kadimastem shareholders holding 84.4% of the combined company. The merger is expected to close on October 30, 2025, with trading under the new name beginning on October 31, 2025. The merger will allow the combined company to advance its clinical programs, including AstroRx® for ALS and IsletRx for diabetes. The merger is seen as growth-positive, with a focus on neurodegenerative diseases and diabetes.
Acquired-byAcquisitionPublic Trading
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $45.35M |
| Last funding | $882K |
| Stage | Mature |
| Rounds | 9 |
| Investors | 11 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.kadimastem.com |
| Careers | Careers page |
Locations
Pinhas Sapir St 7, Ness Ziyyona, Israel
Photos & Videos
1 item(s)
Kadimastem Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsCellsTags (10)
pharma-companiesstem-cellsdiabetesdegenerative-diseasesbioprocessneurologycell-therapyregenerative-medicinebiological-therapyamyotrophic-lateral-sclerosis-(als)Geographic Markets
United StatesKadimastem Financials
$45.35M
Total funding
Undisclosed
Capital raised
$882K
Last funding
Mature
Funding stage
9
Total rounds
11
Investors
Cumulative Funding Raised Over Time ($)
$6.8MApr 2021
$10.0MNov 2021
$15.2MOct 2018
$20.1MOct 2021
Private Equity Funding
PIPE
Nov 2021
$3.2M
Ilex Medical
PIPE
Oct 2021
$5M
Clover Wolf Capital (Lead)
,
Alpha Capital Anstalt
PIPE
Apr 2021
$6.8M
Alpha Capital (Lead), Clover Wolf Capital (Lead)
PIPE
Oct 2018
$5.15M
Altshuler Shaham Investment House, Julien Ruggieri , Michel and Claire Revel, Dr. Michal Izrael, Yehuda Feinberg, Arik Hasson, Yigal Fatran
Non-Equity Funding
GrantEvent
Jul 2025
$882K
BIRD Foundation
GrantEvent
Dec 2022
$1M
BIRD Foundation
GrantEvent
Nov 2018
$750K
EEC Eurostars Program
Public Offering / Exit
DelistingEvent
Oct 2025
Undisclosed
POEvent
Jan 2023
Undisclosed
POEvent
Jun 2013
Undisclosed
Mergers & Acquisitions
MNAEvent
Feb 2025
Undisclosed
Kadimastem Lifecycle
Cumulative Funding Raised Over Time
$6.8MApr 2021
$10.0MNov 2021
$15.2MOct 2018
$20.1MOct 2021
All Events
PIPE
Nov 2021
$3.2M
Ilex Medical
PIPE
Oct 2021
$5M
Clover Wolf Capital (Lead)
,
Alpha Capital Anstalt
PIPE
Apr 2021
$6.8M
Alpha Capital (Lead), Clover Wolf Capital (Lead)
PIPE
Oct 2018
$5.15M
Altshuler Shaham Investment House, Julien Ruggieri , Michel and Claire Revel, Dr. Michal Izrael, Yehuda Feinberg, Arik Hasson, Yigal Fatran
GrantEvent
Jul 2025
$882K
BIRD Foundation
GrantEvent
Dec 2022
$1M
BIRD Foundation
GrantEvent
Nov 2018
$750K
EEC Eurostars Program
DelistingEvent
Oct 2025
Undisclosed
POEvent
Jan 2023
Undisclosed
POEvent
Jun 2013
Undisclosed
MNAEvent
Feb 2025
Undisclosed
Kadimastem News
76 articles
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, announced a reverse share split at a 1-for-10 ratio and a merger with Kadimastem Ltd. The reverse split will affect common and preferred shares, and the company will trade under the new symbol NCEL and name NewcelX Ltd. on Nasdaq starting October 31, 2025. The merger and reverse split were approved at a shareholders meeting on September 29, 2025. The merger aims to enhance the companys focus on innovative therapies for central nervous system disorders. VStock Transfer, LLC will manage the exchange process. The merger is expected to bring potential benefits to both NLS and Kadimastem shareholders.
Acquired-byPublic Trading
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for...
NLS Pharmaceutics Ltd., a biopharmaceutical company, has merged with Kadimastem Ltd., a clinical-stage cell therapy company. The merger will form NewCelX Ltd., which will continue the development of the ITOL-102 cell therapy program for Type 1 Diabetes. This program, supported by the BIRD Foundation, aims to develop a stem-cell-derived therapy for diabetes without lifelong immunosuppression. The merger is seen as a strategic move to expand NLSs pipeline into regenerative and metabolic medicine. The collaboration with iTolerance Inc. will continue under the new company, enhancing the development of innovative therapies.
Acquired-byProduct StagePartners
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced...
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced the completion of all material conditions for their merger, which will result in the formation of a new company, NewCelX Ltd. The merger has been approved by Nasdaq, and the new company will be listed on the Nasdaq Capital Market under the ticker symbol NCEL starting October 31, 2025. Kadimastems shares will be delisted from the Tel Aviv Stock Exchange following the merger. The exchange ratio for the merger is set at 0.706 NLS common shares per Kadimastem ordinary share after a reverse share split. The merger is expected to enhance the companies capabilities in developing therapies for central nervous system disorders and neurodegenerative diseases.
Acquired-byPublic Trading
growth-positive
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
Kadimastem, a clinical-stage biotechnology company, has signed a Memorandum of Understanding (MOU) with TargetGene Biotechnologies to collaborate on developing gene-edited cell therapy products. This partnership aims to enhance the therapeutic performance, stability, and safety of cell-based treatments for diseases like ALS and diabetes. The collaboration will continue under the combined company, NewCelX, following the anticipated merger between NLS Pharmaceutics and Kadimastem. The MOU outlines joint R&D activities, technology exchange, and future licensing opportunities, marking a significant step in Kadimastems strategy to expand its pipeline with next-generation therapies. The collaboration is expected to accelerate the creation of scalable, commercially viable treatments, reinforcing Kadimastems commitment to delivering transformative solutions to patients worldwide.
Partners
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on...
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, and Kadimastem Ltd., an advanced clinical-stage cell therapy company, announced a merger. The merger will result in the formation of NewcelX Ltd., with Kadimastem shareholders holding 84.4% of the combined company. The merger is expected to close on October 30, 2025, with trading under the new name beginning on October 31, 2025. The merger will allow the combined company to advance its clinical programs, including AstroRx® for ALS and IsletRx for diabetes. The merger is seen as growth-positive, with a focus on neurodegenerative diseases and diabetes.
Acquired-byAcquisitionPublic Trading
growth-positive
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, is set to merge with Kadimastem Ltd., an advanced clinical-stage cell therapy company. The merger will result in the formation of a new entity, NewcelX Ltd., which will trade on the Nasdaq Capital Market under the symbol NCEL. The merger is expected to close on October 30, 2025, with the transition to the new trading name beginning on October 31, 2025. Kadimastem shareholders will hold 84.4% of the combined company, while NLS shareholders will retain 15.6% ownership. This merger is seen as a strategic move to enhance the companies capabilities in treating CNS disorders and neurodegenerative diseases.
Acquired-by
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous...
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, and Kadimastem Ltd., an advanced clinical-stage cell therapy company, have announced shareholder approval for their merger. This merger will create NewCelX Ltd., a Nasdaq-listed company, combining NLSs CNS small-molecule expertise with Kadimastems cell therapy programs. The merger aims to position NewCelX as a transatlantic biopharma leader with a diversified pipeline, including a Phase 2a ALS study and a diabetes program. The combined company will be led by Ronen Twito as CEO, with a new board of directors. The merger is expected to enhance growth and global reach, pending final Nasdaq approval.
Acquired-byAcquisitionPublic TradingManagement Changes
growth-positive
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, has announced the approval of its merger with Kadimastem Ltd., an advanced clinical-stage cell therapy company. The merger, approved by NLS shareholders, will create NewCelX Ltd., a Nasdaq-listed company under the ticker NCEL. This merger combines Kadimastems advanced cell therapy programs with NLSs CNS small-molecule expertise, creating a diversified pipeline. The new company will have an experienced leadership team, with Ronen Twito as Executive Chairman and CEO, and Prof. Michel Revel as Chief Scientific Officer. The merger marks a significant step in creating a transatlantic biopharma leader.
Acquired-byPublic TradingManagement Changes
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous...
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, and Kadimastem Ltd., an advanced clinical-stage cell therapy company, have announced the effectiveness of their merger registration statement by the U.S. SEC. The merger will result in the formation of NewCelX Ltd., a publicly traded biotechnology company on Nasdaq. This merger combines Kadimastems cell therapy platforms with NLSs small-molecule therapies, expanding their therapeutic scope in CNS disorders and metabolic diseases. The merger is expected to enhance their global reach and access to U.S. capital markets. Kadimastem is advancing its AstroRx® for ALS and IsletRx for diabetes, with regulatory and clinical preparations underway.
Acquired-byAcquisition
growth-positive
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, and Kadimastem Ltd., an advanced clinical-stage cell therapy company, have announced the effectiveness of their merger registration statement by the SEC. The merger, set to form NewCelX Ltd., will combine NLSs expertise in small-molecule therapies with Kadimastems cell therapy platforms. The new entity will remain publicly traded on Nasdaq under the ticker NCEL. Kadimastem is preparing for a Phase 2a clinical trial of AstroRx® for ALS and advancing its diabetes program, IsletRx, with support from the BIRD Foundation. The merger aims to create a diversified pipeline addressing CNS disorders and metabolic diseases.
Acquired-byAcquisition
growth-positive
NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients
NLS Pharmaceutics Ltd. announced that its merger partner, Kadimastem Ltd., has been granted a patent in Hong Kong for its proprietary cell selection and enrichment technology used in the development of IsletRx, a stem cell-derived therapy for insulin-dependent diabetes. This patent complements existing patents in Europe, the United States, and India, enhancing the global IP protection for IsletRx. The patent is seen as a strategic milestone for Kadimastems diabetes program, supporting clinical development and future commercialization in Asia. The prevalence of diabetes in Hong Kong underscores the importance of this development, as the region represents a significant market and gateway into Mainland China.
Acquired-by
growth-positive
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy
Kadimastem, in collaboration with iTolerance, has received additional funding from the BIRD Foundation to advance the development of iTOL-102, a potential cure for Type 1 diabetes. The funding follows a successful Pre-IND meeting with the FDA, which provided guidance for the clinical development pathway. The BIRD Foundations milestone payment of approximately $166,000 USD is part of a larger support package totaling nearly $882,352 USD. This financial backing underscores the progress and promise of iTOL-102, which aims to offer a cure without lifelong immunosuppression. The companies are preparing to initiate First-in-Human clinical trials.
Product StageInvestment
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders,...
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, announced a milestone-based funding payment from the BIRD Foundation to Kadimastem Ltd. and iTolerance, Inc. for the co-development of iTOL-102, a novel cell therapy for Type 1 diabetes. The funding follows a successful Pre-IND meeting with the FDA, which provided guidance for initiating First-in-Human clinical trials. The BIRD Foundations financial support, totaling nearly $882,352 USD, reflects confidence in the collaborations scientific and regulatory progress. The iTOL-102 program aims to offer a functional cure for Type 1 diabetes without lifelong immunosuppression. The companies are preparing for safety toxicology studies and clinical trial submissions.
Product StagePartnersInvestment
growth-positive
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, has completed the second closing of its $3 million equity financing, raising an additional $1 million. This financing supports its pending merger with Kadimastem Ltd., a clinical-stage cell therapy company. The merger aims to advance treatments for CNS disorders, ALS, and diabetes. The funds will also support working capital and general corporate activities. The merger is subject to regulatory and shareholder approvals. The successful financing round reflects investor confidence in the strategic vision of NLS and Kadimastem, positioning them to advance their diversified pipeline in CNS and regenerative medicine.
InvestmentAcquired-by
growth-positive
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, has made significant progress since Q4 2024. The company completed major financing events in Q1 2025, raising $2.5 million through equity financing and securing a $25 million equity facility commitment to support its merger with Kadimastem Ltd. NLS has raised over $6 million to support the merger and clinical trials post-merger. The company announced positive preclinical and clinical developments, including promising data for its CNS disorder therapies and a successful Pre-IND meeting with the FDA for a Type 1 Diabetes treatment. The merger with Kadimastem, approved by both companies boards and Kadimastems shareholders, is a strategic move to combine their strengths.
InvestmentAcquired-byProduct Stage
growth-positive
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, is set to present new preclinical data on Mazindol ER at the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology. The study, conducted in collaboration with Key-Obs SAS and other European academic institutions, shows that Mazindol significantly reduces the rewarding effects of fentanyl and alleviates withdrawal symptoms in rodent models. These findings suggest Mazindols potential as a non-opioid therapeutic for fentanyl dependence. The company plans to further explore these results in clinical trials, including the upcoming NLS-6002 study. The presentation will take place on May 29, 2025, in Scottsdale, Arizona.
Product StagePartners
growth-positive
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, announced positive results from a preclinical study evaluating Mazindols efficacy in treating fentanyl use disorder. The study, conducted by Key-Obs SAS, showed that Mazindol could significantly reduce fentanyl-induced conditioned place preference in mice, suggesting its potential as a non-opioid treatment for opioid addiction. This development is crucial as the U.S. faces a severe opioid crisis, with fentanyl being a leading cause of overdose deaths. The U.S. market for opioid and substance use disorder treatment is projected to grow significantly, highlighting the importance of innovative therapies like Mazindol. The study supports Mazindols potential expansion into high-value markets beyond ADHD and narcolepsy.
Product Stage
growth-positive
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, announced a strategic merger with Kadimastem Ltd., a clinical-stage cell therapy company. The merger aims to create a Nasdaq-traded biotechnology company with a strong portfolio of advanced therapies for central nervous system disorders and diabetes. The merger is expected to close in the second quarter of 2025, pending regulatory approvals and shareholder consent. Additionally, Kadimastem, in collaboration with iTolerance Inc., has made progress in diabetes treatment, completing a pre-IND meeting with the FDA for a potential breakthrough therapy for Type 1 Diabetes. The merger and advancements in diabetes treatment highlight the companys growth potential in the biotechnology sector.
Acquired-byPublic Trading
growth-positive
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Kadimastem Ltd., in collaboration with iTolerance Inc., announced the results of a Type B pre-IND meeting with the FDA regarding the development of iTOL-102, a potential cure for Type 1 Diabetes. iTOL-102 combines Kadimastems allogenic human stem cell-derived pancreatic islets with iTolerances immunomodulator. The meeting is a significant milestone in the clinical development of iTOL-102, which has shown promising results in animal models. The collaboration is partly funded by grants from the Israel-U.S. Binational Industrial Research and Development Foundation. The companies are preparing for a safety toxicology study and a First-in-Human clinical trial, aiming for regulatory approvals for commercialization.
Product StagePartners
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage company specializing in...
Kadimastem, in collaboration with iTolerance, is advancing the clinical development of iTOL-102, a potential cure for Type 1 Diabetes that eliminates the need for chronic immune suppression. The companies recently held a Type B pre-IND meeting with the FDA, marking a significant milestone in their development process. The collaboration is supported by grants from the Israel-U.S. Binational Industrial Research and Development Foundation. iTOL-102 has shown promising results in preclinical studies, demonstrating functional insulin release and disease reversal in animal models. The partnership aims to leverage Kadimastems stem cell-derived pancreatic islets and iTolerances immunomodulator technology. The companies are preparing for a First-in-Human clinical trial and are working closely with the FDA to advance their innovative diabetes treatment.
Product StagePartnersPublic Trading
growth-positive
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, is set to merge with Kadimastem Ltd., a clinical-stage cell therapy company. This merger aims to revolutionize diabetes treatment by combining the core competencies of both organizations to create a comprehensive solution for diabetes management. The merger is expected to address the multifaceted challenges of diabetes, which is more than just a metabolic disorder, affecting the central nervous system, immune function, and cellular metabolism. NLS is pioneering a new therapeutic approach called DOXA, which integrates orexin receptor agonism, neuroprotective pathways, and metabolic regulation to manage diabetes and its systemic complications.
Acquired-by
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of...
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, is merging with Kadimastem Ltd., a clinical-stage cell therapy company. The merger, approved by Kadimastems shareholders, aims to create a combined Nasdaq-traded biotechnology company focusing on advanced therapies for neurodegenerative diseases and diabetes. The merger is seen as a significant step forward, with both companies committed to advancing innovative solutions in biotechnology. The merger process is ongoing, with NLS planning a shareholder meeting for final approval. The collaboration underscores the companies commitment to addressing unmet medical needs in the biopharmaceutical sector.
Acquired-by
growth-positive
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, is merging with Kadimastem Ltd., a clinical-stage cell therapy company. The merger was approved by Kadimastems shareholders, marking a significant milestone in creating a combined Nasdaq-traded biotechnology company. This merger aims to leverage the strengths of both companies to advance innovative therapies for neurodegenerative diseases and diabetes. NLS plans to hold a shareholder meeting for final approval. The collaboration highlights a commitment to addressing unmet medical needs in the biopharmaceutical sector. The merger is expected to unlock new growth opportunities and foster innovation.
Acquired-by
growth-positive
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence. This initiative addresses the urgent need for non-opioid treatment options amid the global opioid crisis, particularly the rise in fentanyl addiction. Mazindol ER, a tetracyclic compound, targets multiple neurotransmitter systems to potentially mitigate opioid dependence. The program aims to explore its unique pharmacological profile, which includes modulation of the 5-HT1A receptor, partial interaction with the mu-opioid receptor, and partial agonism of the orexin-2 receptor. The company is committed to developing innovative therapies for complex central nervous system disorders.
Product Stage
growth-positive
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS
Kadimastem, a clinical-stage cell therapy company, is nearing the completion of its merger with NLS Pharmaceutics, a Swiss biopharmaceutical company. The merger aims to create a combined Nasdaq-traded biotechnology company with a strong pipeline of advanced therapies. A special general meeting of Kadimastems shareholders has been convened to approve the merger, following approval from the Central District Court in Israel. NLS has recently closed an initial $500,000 of a $1 million fundraising round, with a share price significantly above market value, and previously disclosed a $3.2 million investment in October 2024. This merger is seen as a pivotal step towards innovation and growth in the biotechnology sector.
Acquired-byInvestment
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of...
Kadimastem, a clinical-stage cell therapy company, is approaching the final steps to complete a merger with NLS Pharmaceutics, a Swiss biopharmaceutical company. The merger aims to create a combined Nasdaq-traded biotechnology company with a robust pipeline of advanced therapies. Kadimastem has called a special general meeting to secure shareholder approval for the merger, which has been expedited by the Central District Court in Israel. NLS Pharmaceutics has recently closed a $500,000 investment round, part of a larger $1 million fundraising effort, to facilitate the merger. The merger is expected to enhance value for shareholders and redefine the biotechnology landscape.
Acquired-byInvestment
growth-positive
/PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of...
Kadimastem, a clinical-stage cell therapy company, is nearing the completion of its merger with NLS Pharmaceutics, a Swiss biopharmaceutical company. The merger aims to create a combined Nasdaq-traded biotechnology company with a strong pipeline of advanced therapies. Kadimastem has called a special general meeting of its shareholders to approve the merger, which has been expedited by the Central District Court in Israel. NLS has recently closed a $500,000 investment round, part of a larger $1 million fundraising effort, to facilitate the merger. The merger is expected to enhance shareholder value and redefine the biotechnology landscape. Both companies are focused on developing innovative therapies for neurodegenerative diseases and diabetes.
Acquired-byInvestment
growth-positive
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, announced the successful completion of an initial $500,000 financing as part of a $1 million agreement with an accredited investor. This financing supports NLSs proposed merger with Kadimastem Ltd., a clinical-stage cell therapy company. The merger aims to create a combined Nasdaq-traded biotechnology company with advanced clinical development product candidates. The financing, along with a previous $3.2 million investment, strengthens NLSs capacity to complete the merger. The merger is expected to enhance strategic positioning in the biotechnology sector and deliver value to shareholders. NLS has filed an F-4 Registration Statement with the SEC and plans to convene an extraordinary general meeting for merger approvals.
InvestmentAcquired-by
growth-positive
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, is set to merge with Kadimastem Ltd., an Israeli cell therapy company. The merger aims to create a Nasdaq-traded biotechnology company with advanced clinical product candidates and a focus on allogeneic cell therapy. NLS has filed a Registration Statement with the SEC, which includes a prospectus for the merger and a proxy statement for NLS shareholders. The merger, announced on November 5, 2024, is subject to shareholder approval and SEC requirements. Kadimastem plans to become publicly traded on Nasdaq through this merger, which is expected to enhance its technological capabilities and shareholder value.
Acquired-byPublic Trading
growth-positive
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
NLS Pharmaceutics and Kadimastem are working towards a merger expected to close by January 2025. The merger aims to enhance the combined companys pipeline, particularly in innovative therapies for neurodegenerative diseases and diabetes. Kadimastem, in collaboration with iTolerance, has submitted a request for a Pre-IND meeting with the FDA for iTOL102, a potential treatment for Type 1 Diabetes. This collaboration, funded in part by the BIRD Foundation, combines Kadimastems IsletRx and iTolerances immunomodulatory technology. The merger and the Pre-IND submission represent significant steps towards advancing diabetes treatment and expanding the companies therapeutic offerings.
Acquired-byPartners
growth-positive
NLS Pharmaceutics expects to close Kadimastem merger by end of January
NLS Pharmaceutics has announced significant progress with its Dual Orexin Receptor Agonist (DOXA) platform, aimed at addressing sleep and neurodegenerative diseases. The company is conducting preclinical studies on two candidates, AEX-41 and AEX-2, which show promise in managing narcolepsy. NLS has regained full compliance with Nasdaq listing requirements and has strengthened its financial position through successful fundraising, including a $3.2 million private placement in October 2024 and another up to $1 million in December. Additionally, NLS plans to merge with Kadimastem, enhancing its strategic position and expanding its pipeline. The merger will allow NLS shareholders to benefit from the potential sale of legacy assets like Mazindol.
InvestmentAcquired-byPartners
growth-positive
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Biotechnology company Pluri Inc. has signed a tech transfer and manufacturing agreement with Kadimastem Ltd., a clinical stage biotechnology company. PluriCDMO™, Pluris contract development and manufacturing organization, will manufacture two cell therapy product candidates for Kadimastem. The collaboration will enhance Kadimastems capacity to manufacture their products under good manufacturing practice (GMP) conditions, preparing them for clinical trials and expansion into the U.S. market.
PartnersExpand
Growth-Positive
IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market
IM Cannabis Corp., a leading medical cannabis company with operations in Israel and Germany, has announced the termination of the preliminary term sheet signed with Kadimastem Ltd. The termination comes as a result of accelerated growth in Germany following the legalization of cannabis. As part of the termination agreement, a loan provided to IMC Holdings Ltd by Kadimastem, totaling $300,000, will be repaid with 9% annual interest in three installments by July 31, 2024.
PartnersInvestment
growth-positive
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC
Kadimastem, a leading cell therapy company, is moving closer to signing a merger agreement with NASDAQ listed company IMCC. As part of the agreement, Kadimastem will provide IMCC with a loan of up to $650,000 to restructure its current operations for sale, allowing Kadimastem to enter the public platform on the NASDAQ. The merger will result in Kadimastem shareholders holding 88% of the shares of the combined company, and Kadimastem will cease trading on the Tel Aviv Stock Exchange. The merger is in line with Kadimastems strategic plan to approach its target markets and the US capital markets.
Public TradingAcquisition
growth-positive
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company
IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, has announced a reverse merger with Israel-based Kadimastem Ltd, a clinical cell therapy public company. The merger will see Kadimastem shareholders hold 88% of the common shares of the resulting issuer, with IMC shareholders holding the remaining 12%. Prior to the merger, IMCs existing medical cannabis operation and other activities in Israel and Germany will be restructured. The merger is expected to change the business from medical cannabis to biotechnology.
Acquired-byManagement ChangesInvestment
growth-positive
Kadimastem plans listing on Nasdaq through merger
Israeli stem cell company Kadimastem plans to merge with an undisclosed Canadian company listed on Nasdaq and delist from the Tel Aviv Stock Exchange (TASE). Post-merger, Kadimastems shareholders will own 88% of the merged entity. The company, which is developing stem cell-based treatments for diseases like ALS and diabetes, has lost 98% of its value since its IPO on the TASE. Kadimastems management believes that listing on Nasdaq will facilitate access to larger amounts of capital, aiding the companys development and progress towards its target markets in the U.S.
Acquired-byPublic TradingManagement Changes
growth-positive
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq
Kadimastem Ltd., a cell therapy company, has announced a non-binding agreement for a merger with a NASDAQ-traded public company. Post-merger, Kadimastem shareholders are expected to hold 88% of the shares of the combined company and Kadimastem will cease trading on the Tel Aviv Stock Exchange. The company has committed to having approximately $5 million in funds, including capital raised simultaneously with the completion of the transaction. The move aligns with Kadimastems strategic plan to approach its target markets and the US capital markets. The company recently received FDA approval for a Phase IIa multi-site clinical trial in the US for the treatment of ALS.
Acquired-byPublic TradingInvestment
Growth-Positive
Kadimastem Receives Patent for Its
Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
Kadimastem Ltd., a clinical stage cell therapy company, has been granted a patent from the Indian Patent and Trademark Office for its cell therapy technology. The patent covers the production of IsletRx, the companys product for the treatment and potential cure for diabetes. The patent approval strengthens the company’s global position in the diabetes field. The company is also collaborating with iTolerance, a US company in the diabetes field, on a project funded by the BIRD Foundation. The project aims to develop and commercialize a breakthrough regenerative technology to cure diabetes without the need for life-threatening chronic immuno-suppression.
InvestmentPartners
growth-positive
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
Kadimastem Ltd., a clinical stage cell therapy company, has been granted a patent from the Indian Patent and Trademark Office for its cell therapy technology. The patent covers the production of IsletRx, the companys product for the treatment and potential cure for diabetes. The approval of this patent is significant, especially in light of Kadimastem’s collaboration with iTolerance, a US company in the diabetes field. The project received a US $1 Million grant from the BIRD Foundation. India, with its rapidly growing economy and increasing investments in web infrastructure and pharma and biotech sectors, is a key market for biotech companies.
InvestmentPartners
growth-positive
A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology
Kadimastem, a biotech company specializing in cellular therapy, has announced the publication of a peer-reviewed article in the Journal of Clinical Toxicology. The article details the development and safety of Kadimastems cryopreserved AstroRx cell product, which is intended for the treatment of ALS. The product is derived from embryonic stem cells and is designed to increase the survival of neurons. The development of this cryopreserved cell therapy product will allow for more accurate sterility testing, simplified manufacturing scaling, and improved therapy delivery timing. The product will be used in an upcoming phase IIa clinical trial involving 30 ALS patients.
InvestmentExpand
growth-positive
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
On January 22, 2024, Kadimastem and iTolerance announced their initial targeted engagement for regulatory advice on CBER products with the U.S. FDA. The companies are advancing joint clinical development of iTOL-102, a potential cure for diabetes that does not require chronic immune system suppression. The companies received feedback from the FDA on their preclinical plans, which they intend to use for the advancement of their potential joint collaboration development plans. In May 2023, the companies received a grant of US$1.0 million from the Binational Israel-U.S. Industrial R&D (BIRD) Foundation for their research collaboration.
PartnersInvestment
growth-positive
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes
Kadimastem Ltd. and its American partner iTolerance Inc. have submitted a request to the FDA for a preliminary meeting regarding their joint diabetes treatment, iTOL-102. The companies had signed a collaboration agreement a few months ago to co-develop cell technology as a potential cure for diabetes without the need for chronic immunosuppression. They received a total grant of about US$1 million from the international BIRD fund. The companies are also considering expanding their cooperation and advancing the development of iTOL-102.
PartnersInvestment
growth-positive
iTolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes
Regenerative medicine company iTolerance, Inc. and clinical stage cell therapy company Kadimastem Ltd. have submitted a meeting request to the INTERACT committee of the U.S Food and Drug Administration (FDA) for iTOL-102, a potential cure for Type 1 diabetes. This is the first step in a three-step process to design and commence an FDA-approved clinical study of iTOL-102. The companies had previously announced a research collaboration agreement to co-develop and commercialize a regenerative technology to cure diabetes, and received a grant of US$1 million from the Binational Israel-U.S. Industrial R&D (BIRD) Foundation.
PartnersInvestment
growth-positive
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
Kadimastem Ltd. has been granted a patent from the United States Patent and Trademark Office for its cell therapy technology. The patent covers the production of IsletRx, the companys product for the treatment and potential cure for diabetes. The approval of this patent is important for the companys collaboration project with iTolerance and the BIRD Foundation to develop a regenerative technology to cure diabetes. The project will receive a $1 million grant from the BIRD Foundation. The article also highlights the social and financial burden of diabetes in the United States. Kadimastems treatment aims to improve the quality of life for those with insulin-dependent diabetes. The IsletRx product is a collection of pancreatic islet cells that can detect sugar levels in the body and produce insulin and glucagon as needed.
CustomersPartnersInvestment
growth-positive
Kadimastem Granted European Patent for Its
Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
Kadimastem Ltd., a clinical stage cell therapy company, has been granted a European patent for its cell therapy technology, IsletRx, used in the treatment of diabetes. This is the fourth global patent approval for the companys innovative cell selection and enrichment technology. The patent provides crucial protection to Kadimastems core Islet cell sorting technology, which is critical for achieving an effective cell therapy product for the treatment of diabetes. The European market holds great potential for this technology, with the Europe Region having the highest number of children and adolescents with type 1 diabetes.
Customers
growth-positive
Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation
Kadimastem has signed a collaboration agreement with iTolerance to develop a potential cure for diabetes without the need for chronic immune system suppression. They have received a grant of US$1 million from the BIRD Foundation to support their joint project. Kadimastem will supply its advanced cell product called IsletRx, while iTolerance will provide its technology (iTOL-100) for the transplantation of allogeneic cells without tissue matching and immunosuppression. The funding will be used to develop iTOL-102, an allogeneic cell product utilizing stem cell-derived pancreatic islets. The total budget for the project is US$2 million, with the grant covering half of the amount. The collaboration aims to bring a joint product to the clinic and improve the lives of diabetics worldwide.
PartnersInvestment
growth-positive
Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation | MarketScreener
Kadimastem has signed a collaboration agreement with iTolerance Inc. to co-develop and commercialize a regenerative technology for curing diabetes without immunosuppression. The companies received a milestone payment of NIS 3.65 million (US$1 million) from the Israel-U.S. Binational Industrial R&D Foundation. Kadimastem will provide its cell product IsletRx, while iTolerance will contribute its technology iTOL-100. The funding will support the joint project to develop iTOL-102, an allogeneic cell product for diabetes treatment. The total budget for the project is US$2 million, with the grant covering US$1 million. The collaboration is seen as a vote of confidence in the scientific potential and innovation of both companies. Kadimastem CEO Asaf Shiloni expressed excitement about the collaborations potential to improve the lives of millions of diabetics worldwide.
Partners
growth-positive
Kadimastem Earns FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS | News Direct
Kadimastem Ltd. has received FDA approval to commence a phase IIa clinical trial in the US for its lead neurological cell therapy product AstroRx® to treat ALS. The trial will involve repeated dosing of AstroRx® every three months. In a previous phase I/IIa clinical trial conducted in Israel, Kadimastem demonstrated a good safety profile and a decline in disease progression. AstroRx® contains healthy astrocytes derived from human embryonic stem cells and aims to support the survival of diseased motor neurons in ALS patients. The FDA approval is seen as a major achievement for Kadimastem and brings hope for ALS patients. The company plans to recruit eligible ALS patients for the clinical trial.
Customers
growth-positive
AstroRx safe and slows ALS progression in Phase 1/2 clinical trial...
Kadimastems experimental cell-based therapy AstroRx showed promising results in slowing disease progression in ALS patients. The therapys benefits began to wane after three months, indicating that repeat injections may be necessary to prolong its effect. Kadimastem plans to launch a Phase 2a clinical study in the U.S. to further examine the effects of AstroRx injections. The studys full data were published in the Journal of Translational Medicine.
Customers
growth-positive
Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for the Treatment of ALS | News Direct
Kadimastem Ltd. has submitted an IND application to the FDA for a phase IIa clinical trial of its lead neurological cell therapy product, AstroRx, for the treatment of ALS. The trial will test the repeated administration of AstroRx every 3 months to prolong the therapeutic effect observed in a previous clinical trial. The company aims to slow the progression of ALS, improve quality of life, and extend life expectancy for patients. Kadimastem is a biotech company specializing in cellular therapy and is also developing a potential cure for diabetes. The submission of the IND application is a major milestone for the company, and pending FDA approval, the trial will be conducted at multiple sites. Kadimastem has been awarded multiple patents and is in discussions with potential partners to advance its ALS and diabetes programs.
Customers
growth-positive
Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational
Medicine
Kadimastem announced the publication of its successful Phase I/IIa clinical trial results for its cell therapy product, AstroRx®, in patients with ALS. The trial demonstrated that AstroRx® was safe and well-tolerated, with a clinically meaningful effect observed in the first 3 months after treatment. The company plans to conduct a Phase IIa clinical trial with repeated doses of AstroRx®. Kadimastem is a biotech company focused on developing innovative products for the treatment of ALS and diabetes.
Customers
growth-positive
Kadimastem Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening
Kadimastem Ltd. has been awarded a patent in Australia for its AstroRx® technology for the treatment of ALS and drug screening. This patent strengthens the companys assets for the planned Phase IIa clinical trial in the U.S. Kadimastem already holds patents for the product in the US, Europe, Japan, and Israel. The patent protects the manufacturing technology of AstroRx® and the use of the companys platform cell-based drug screening technology. AstroRx® contains astrocytes, which are impaired in ALS patients. The companys assumption is that injecting healthy astrocytes into the spinal cord fluid of ALS patients will slow the progression of the disease. Kadimastem completed a Phase I/IIa clinical trial with positive results. The company plans to file an IND submission to begin clinical trials in the U.S.
Customers
Growth-Positive
Kadimastem Awarded Patent In Australia For Its Astrorx® Tech...
Kadimastem Ltd., a clinical stage cell therapy company, has received a patent from the Australian Patent Office for production technology of AstroRx®, a treatment for ALS and a potential cure for diabetes. This patent accompanies the companys patents in the US, Europe, Japan, and Israel. The patent protects the manufacturing technology of AstroRx® and the companys platform cell-based drug screening technology. The company completed a clinical trial (Phase I/IIa) in which the cells were injected into the spinal cord fluid of 10 ALS patients, demonstrating a high safety profile and a clinically meaningful effect.
InvestmentExpand
growth-positive
Kadimastem Announces it raised appx 7.5 million NIS by rights offering
Kadimastem Ltd., a cell therapy company, has raised 7.5 million NIS in a rights offering. The companys main stakeholders and European Alpha Capital Anstalt participated in the offering. They also received a budget grant of 3.5 million NIS from the Israel-U.S. Binational Industrial R&D Foundation. Kadimastem is preparing to submit an IND to the FDA for a clinical trial for their ALS treatment. They are also in negotiations with a French company for a joint product in the field of diabetes. The company is planning a dual listing on NASDAQ and is exploring a strategic investment or cooperation with a private company. The raise from stakeholders gives a boost to the companys development plan.
InvestmentExpand
growth-positive
Kadimastem Announces It Raised Appx 7.5 Million NIS By Right...
Kadimastem Ltd., a cell therapy company, has raised 7.5 million NIS in a rights offering. The companys main stakeholders and European Alpha Capital Anstalt participated in the offering. The company also received a budget grant of 3.5 million NIS from the Israel-U.S. Binational Industrial R&D Foundation for a joint project with iTolerance Inc. to develop a regenerative technology for diabetes. Kadimastem plans to submit an IND to the FDA for a clinical trial for ALS treatment and is in negotiations with Defymed for a joint product in the field of diabetes. The company is also preparing for a dual listing on NASDAQ and exploring a strategic investment or cooperation with a private company. The stakeholders support boosts the companys development plan and potential.
Investment
growth-positive
Kadimastem and iTolerance's Proposed Collaboration Further Strengthened With Receipt of US $1 Million BIRD Foundation Gran | News Direct
Kadimastem and iTolerance have received a $1 million grant from the BIRD Foundation to support their joint project to develop a potential cure for diabetes. The project aims to develop a breakthrough regenerative technology that does not require chronic immune system suppression. Kadimastems diabetes product, IsletRx, will be combined with iTolerances platform technology, iTOL-100, to create iTOL-102, an allogeneic cell product that can be transplanted without the need for chronic immunosuppressive treatments. The grant will cover half of the proposed project budget and will be allocated over a period of 30 months. The goal is to start clinical trials of iTOL-102 within the grant period and bring the cure for diabetes to market.
Investment
Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory
growth-positive
Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory | BioSpace
Kadimastem Ltd. has received patent approval for its cell selection and enrichment technology used in the development of its IsletRx treatment for diabetes. This is the companys third patent approval, following approvals in Japan and Australia. The approval in Israel strengthens the companys global leadership and provides a competitive advantage for future collaborations, such as the recently signed agreement with Implant Therapeutics, Inc. Kadimastem aims to increase its cell production capacity and conduct further pre-clinical trials of IsletRx. The companys technology allows for the selection and enrichment of high-quality islet cells from pluripotent stem cells, enabling maximum therapeutic effect. The patent approval reinforces the companys intellectual property and positions it for future advancements in its diabetes program.
CustomersPartners
growth-positive
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
Kadimastem, a cell therapy company, has received a patent from the United States Patent and Trademark Office for its cell therapy technology for treating ALS and other neurodegenerative diseases. The patent strengthens the companys intellectual property portfolio and supports the Phase IIa study of its flagship product, AstroRx®, for ALS. AstroRx® is a breakthrough technology that uses astrocytes derived from human pluripotent stem cells to support the survival of neurons in the central nervous system. The company plans to test repeated doses of AstroRx® in a clinical trial to slow the progression of ALS. Kadimastem estimates that the potential size of the ALS market could reach approximately $0.5 billion annually. The company is preparing to submit an IND by the end of 2022 and start the Phase IIa study in the US in 2023.
Customers
growth-positive
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of "Immune Evasive" Cells News Direct
Kadimastem has signed an evaluation agreement with Implant Therapeutics for the potential licensing of Immune Evasive cells. The agreement involves conducting a feasibility study to test if Implant Therapeutics iACT cells can provide a solution to the challenge of transplant immune protection and avoidance of rejection for Kadimastems IsletRx diabetes treatment. If successful, the study could lead to the licensing of Implant Therapeutics technology by Kadimastem. This agreement is a significant step forward towards pancreatic tissue engineering and the development of a cure for diabetes. Kadimastem aims to create glucose sensing, insulin-producing pancreatic cells that are not rejected by the immune system. The ultimate goal is to improve the lives of people living with diabetes worldwide.
Partners
growth-positive
קדימהסטם מקבלת מענק של 10 מיליון ש"ח מהרשות לחדשנות
קדימהסטם, a biotechnology company, has received a grant of 10 million₪ for the development of its cell therapy for ALS. The grant will be used for clinical trials in the US and for expanding the production of the companys cell-based product. The company expects the clinical trial to begin in early 2023. This grant, along with a previous grant received by the company, demonstrates support for the companys innovative treatment and its potential to benefit ALS patients worldwide. The article highlights the companys progress in developing its breakthrough therapy and its preparations for an international clinical trial.
Investment
growth-positive
Kadimastem seeks Nasdaq listing, raises $3.2m from ILEX
Kadimastem, a clinical stage cell therapy company, has raised NIS 10 million ($3.2 million) in a private financing round from ILEX Medical. The investment will be used to finance the clinical development of AstroRx for the treatment of ALS and IsletRx for insulin-dependent diabetes. Kadimastem also announced its intention to pursue a NASDAQ listing. The company has raised over NIS 50 million ($15.9 million) since the beginning of 2021. The investment demonstrates investor confidence in Kadimastem and its cell therapy technology. The companys new leadership team aims to accelerate growth and uplist the company on NASDAQ.
InvestmentPublic Trading
growth-positive
Kadimastem Raises $5 million In Private Placement News Direct
Kadimastem Ltd., a clinical stage cell therapy company, has raised $5 million in a private placement led by Clover Wolf Capital and Alpha Capital Anstalt, along with additional investment from the companys controlling shareholders. The funds will be used to support Kadimastems future clinical trial activity and strategic collaborations in ALS and Diabetes programs. The investors also have an option to purchase an additional $4.7 million in shares in the future. The funding will accelerate the companys development strategy and preparation for clinical trials in the US. Kadimastem has recently achieved several milestones, including a meeting with the FDA, a Japanese patent for its technology, and the publication of a scientific paper. The company aims to lead the field of cell therapy.
Investment
growth-positive
פרופ' מישל רבל, בעל השליטה בקדימהסטם מימש אופציות בהיקף של כ-3.5 מיליון שקל למניות
קדימהסטם, a company developing cell therapies for ALS and diabetes, announced that Prof. Michel Revel, one of the companys founders and controlling shareholders, has exercised options worth approximately 3.5 million shekels. As a result, Prof. Revel will hold about 33% of the companys shares. The company recently underwent management changes, appointing Ronen Tuito as Chairman of the Board and Asaf Shiloni as CEO. Four months ago, the company raised a private funding round of approximately 22.3 million shekels led by Clover Wolf Capital and Alpha Capital Anstalt. The funds will be used for further research and development of the companys platforms and products for ALS and insulin-dependent diabetes.
Investment
growth-positive
Kadimastem Raises NIS 22.3 Million ($6.8 Million) with a Total Potential of NIS 53.4 Million ($16 Million) with Warrants in a Private Placement News Direct
Kadimastem Ltd., a clinical stage cell therapy company, has raised NIS 22.3 million ($6.8 million) in a private placement led by institutional investors Alpha Capital Anstalt and Clover Wolf Capital. The financing will enable Kadimastem to expedite its research and development programs for both lead indications, AstroRx® for the treatment of ALS, and IsletRx for Type 1 diabetes. The financing will also support the companys business development efforts in the US. The CEO and Chairman of Kadimastem expressed confidence in the companys leadership and technology, and believe that the investment will significantly advance the clinical development of their lead product candidates.
Investment
growth-positive
https://www.jpost.com/health-science/promising-stem-cell-based-drug-for-treatment-of-als-receives-patent-661535
Kadimastem, a drug company, has received a patent for its new drug AstroRx to treat Amyotrophic Lateral Sclerosis (ALS). The medication uses embryonic stem cells to create healthy nervous system cells, slowing disease progression and improving quality of life for ALS patients. Kadimastem aims to have a pre-IND meeting with the US FDA to begin the next stage of clinical trials. The companys technology reduces treatment costs and avoids genetic modification. AstroRx completed Phase 1/2a of its clinical trial, with no serious side effects and a decrease in disease progression rate. The drug has been recognized by the FDA as an orphan drug for rare diseases. Kadimastem is traded on the Tel Aviv Stock Exchange.
Customers
growth-positive
Kadimastem hopes to turn corner with new management
Israeli stem cell technology company Kadimastem has appointed Asaf Shiloni as CEO and added three new expert directors to its board. The company hopes that these appointments will help turn its financial situation around and secure a bright future. Shiloni, who previously worked at PeproTech Inc., has experience in establishing collaborations and joint ventures with stem cell companies and research labs. The other appointments include Ronen Twito as co-chairperson of the board and Doron Birger and Ron Mayron as new expert board members. The company is focused on developing and manufacturing cell products for ALS and diabetes.
Management Changes
growth-negative
לאחר התפטרות המנכ"ל: מאבקי שליטה בקדימהסטם בין רבל לדח"צים
The biomed company Kadimastem is experiencing a power struggle between its controlling shareholder, Michel Revel, and its external directors. Revel is attempting to replace all the companys directors following the resignation of CEO Rami Epstein. The external directors have hired a law firm and are pushing back against Revels actions. Kadimastem is currently in the clinical development stage of cell therapies and is traded at a value of 56 million shekels after a 42% increase in the past three months and a 45% decrease since the beginning of the year.
Management Changes
growth-positive
Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS
Kadimastem Ltd., a biotechnology company, announced positive results from its Phase 1/2a clinical trial of AstroRx® in the treatment of ALS. The trial showed a positive efficacy signal and a good safety profile. The company plans to conduct further clinical trials to confirm these effects. The results demonstrated a decline in disease progression rate and improvement in patient quality of life. Kadimastem is now focused on advancing FDA regulatory processes and global multi-center clinical trials. The company has appointed new senior managers to support these processes. AstroRx® is a cell therapy product derived from human Embryonic Stem Cells (hESC) and has been granted orphan drug designation by the FDA. ALS is a neurodegenerative disease with no effective treatment, and Kadimastem aims to provide an innovative therapeutic solution.
Customers
growth-positive
Kadimastem reports positive ALS cell therapy results
Israeli biopharmaceutical company Kadimastem has announced additional results for the first group of patients treated with its drug in a Phase I/IIa cell replacement trial for ALS. After six months of monitoring, no severe side effects were reported, and no toxicity limiting the dosage in treatment was found. The condition of patients improved after three months of treatment, and although deterioration resumed after 5-6 months, it was still slower than expected without treatment. Kadimastem is considering a change in the trial protocol to include higher dosages and repeated injections. The company is satisfied with the results and believes in the potential long-term advantages of administering a higher dosage.
Customers
growth-positive
Stem cell co Kadimastem reports positive ALS results
Kadimastem, a stem cell therapy company, has reported positive interim results from a trial of its treatment for Amyotrophic Lateral Sclerosis (ALS). The trial used fully differentiated cells derived from embryonic stem cells. The development of the disease in the treated patients was significantly slower than the projected rate of deterioration. ALS is a degenerative muscular disease with no known genetic basis. Kadimastems product is based on the use of human brain cells called astrocytes that protect motor nerve cells. The company is also developing a drug for diabetes using embryonic stem cells. Rami Epstein is the CEO of Kadimastem.
Investment
growth-positive
Israeli company plans to make insulin injections obsolete
Israeli biopharmaceutical company Kadimastem is working on creating an in-body device that can produce insulin, eliminating the need for insulin injections for diabetes patients. The company plans to use pluripotent stem cells to create insulin-producing cells and is also developing an encapsulation device to prevent rejection by the immune system. The product is currently in the pre-trial stage and is expected to reach the market within the next decade. Kadimastem is also conducting clinical trials for a stem-cell treatment for ALS disease. The company takes its cells from surplus embryos and may consider using non-embryonic pluripotent cells in the future.
Customers
growth-positive
Israeli and French Biotech Companies Partner to Fight Diabetes With Bio-Artificial Pancreas
Israel-based Kadimastem and France-headquartered Defymed will receive a grant of around $1.5 million from the European Commissions Eurostars program to develop the technology to treat type 1 diabetes.
PartnersInvestment
https://www.pehub.com/2018/10/israeli-biotech-firm-kadmastem-procures-5-15-mln/
growth-positive
Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients
Israeli biotechnology company Kadimastem has enrolled the first patient for its clinical trial in ALS patients using its cell therapy product AstroRx®. The trial, being conducted by the Department of Neurology of the Hadassah Ein-Kerem Medical Center, aims to evaluate the safety and efficacy of AstroRx® in 21 patients. Interim results are expected within the coming year. Kadimastems CEO, Yossi Ben-Yossef, believes that AstroRx® will likely improve the condition of the patients participating in the trial and position the company as a leading company in the cell therapy field. AstroRx® is an innovative cell-based treatment for ALS that replaces damaged astrocytes with healthy cells. Kadimastem develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases.
Customers
growth-positive
Kadimastem jumps on Merck Serono collaboration
Kadimastem has signed a cooperation agreement with Merck Serono to scan drugs for potential treatments for multiple sclerosis and other neurodegenerative diseases. Kadimastem will use its unique platform for Merck Serono in the scanning of potential new drugs. The deal is consistent with Kadimastems strategy of generating revenue in the short term and strengthening its connections with major international pharmaceutical firms.
Partners
Kadimastem Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 29 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Kadimastem Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514192558 |
| Crunchbase | kadimastem |
| Phone | +972737971600 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-07T00:00:00.000Z |
| Created | 2014-11-23T00:00:00.000Z |